Bicara Therapeutics (BCAX) Interest & Investment Income (2023 - 2026)

Bicara Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 18.57% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $16.9 million (up 1.27% YoY), while the FY2025 annual figure was $17.9 million, up 22.56% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $4.1 million, up from $3.8 million in the prior quarter.
• The five-year high for Interest & Investment Income was $5.9 million in Q4 2024, with the low at $13000.0 in Q3 2023.
• The 4-year median for Interest & Investment Income is $3.8 million (2025), against an average of $3.4 million.
• The sharpest annual moves came in 2024 and 2025: Interest & Investment Income jumped 24107.69% in 2024, then slumped 35.41% in 2025.
• Bicara Therapeutics' Interest & Investment Income stood at $1.3 million in 2023, then soared by 350.88% to $5.9 million in 2024, then plunged by 35.41% to $3.8 million in 2025, then climbed by 7.76% to $4.1 million in 2026.
• Business Quant data shows BCAX's Interest & Investment Income at $4.1 million in Q1 2026, $3.8 million in Q4 2025, and $4.4 million in Q3 2025.